The cost, which is confidential and was negotiated for all in all , 300 million doses, is a little lower than the $19.50 per photo the United States agreed to pay for a very first shipment of hundred million doses of the identical vaccine, in series with what Reuters reported in November.
The EU file dated Nov. 18 was circulated internally after the EU announced the supply package of its with Pfizer and its German partner BioNTech on Nov. eleven.
The EU drug regulator is anticipated to decide on Monday on approval for the Pfizer vaccine after the photo was authorised in several countries, including Britain and the United States.
On Thursday Belgian say secretary for the budget Eva De Bleeker released on Twitter a dining room table with prices Belgium will pay pharmaceutical companies for their COVID-19 vaccines. She retracted the piece of writing shortly after posting.
In that dining room table the Pfizer vaccine was suggested as costing Belgium twelve euros ($14.6) a dose, leading many to think that has been the full price agreed by way of the EU.
Various other vaccines in the family table were furthermore shown with prices lower compared to prices disclosed by EU solutions.
“There is always a total price along with a cost upon delivery,” an EU official involved in talks with vaccine makers told Reuters when directed to clarify the difference between the Belgian and EU rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality needs, but pointed to what De Bleeker told the Belgian parliament last week. In this public hearing, De Beeker stated Belgium’s budgeted prices were still partial.
Under EU advance purchase deals for COVID 19 vaccines, the bloc agrees upfront payments with business enterprises to secure doses before they are approved. Following approvals, EU governments are able to pay the rest to get reserved doses.
The EU hasn’t revealed the initial transaction agreed with Pfizer.
Nonetheless, it stated in October which it paid aproximatelly 1 billion euros inside downpayments to AstraZeneca, Sanofi and Johnson and Johnson for the shots of theirs, with a further 1.45 billion euros budgeted for initial payments to Pfizer BioNTech, Curevac and Moderna.
It has since agreed source deals with all 6 companies and is negotiating a seventh agreement with Novavax.